Dr. Mark Hyman warns standard lab panels miss metabolic decay
- Standard lab tests ignore fasting insulin, missing early metabolic dysfunction in millions.
- Muscle loss from GLP-1 drugs drops metabolic rate and triggers weight rebound.
- Direct biomarker testing and AI models bypass slow diagnostic clinical friction.
Standard medicine waits for organ failure before taking a patient seriously.
Dr. Mark Hyman argued on This Week in Startups that standard reference ranges ignore early signals of systemic decline. Fasting glucose, the default metric for metabolic health, only spikes after years of silent damage. Quest Diagnostics orders fasting insulin tests in less than one percent of standard lab panels. Yet data from Function Health shows that 65 percent of its tested members carry elevated fasting insulin despite normal blood sugar.
"Fasting blood sugar is a lagging indicator."
- Dr. Mark Hyman, This Week in Startups
The diagnostic blind spot extends into modern weight-loss treatments. GLP-1 agonists promise effortless weight reduction, but Hyman points out that up to 75 percent of users suffer digestive side effects, with four percent experiencing severe adverse events. Weight lost without resistance training and sufficient protein intake comes largely from muscle mass, destroying baseline metabolic rates and ensuring weight rebounds once injections stop.
Quick pharmaceutical fixes mask systemic decay instead of restoring cellular architecture.
This diagnostic failure plays out aggressively in mental health. On This Week in Startups, Hyman highlighted how doctors routinely prescribe SSRIs and stimulants for biological distress rooted in nutritional deficiencies and brain inflammation. In juvenile detention trial facilities, replacing ultra-processed food with whole foods reduced violent incidents by 97 percent, proving that behavioral issues often stem from nutrient deficits rather than inherent psychiatric defects.
"Brain health begins in the gut and metabolic system, not in a prescription bottle."
- Dr. Mark Hyman, This Week in Startups
The alternative requires moving past the conventional doctor-patient bottleneck. One in three Americans currently delays medical care due to prohibitive costs. Function Health offers direct access to 160 biomarkers twice a year for a dollar a day, replacing $15,000 concierge panels. By using large language models to interpret multi-omic data alongside physician validation, patients can catch trajectories toward Alzheimer's or diabetes long before symptoms trigger a hospital visit.
Health requires continuous biological tracking, not delayed crisis management.